S Stevens Negus

For discussion of preclinical strategies in analgesic drug development: Core Outcome Measures in Preclinical Assessment of Candidate Analgesics. Pharm Rev 7:225-266, 2019 PMID: 30898855

@maiasz Maia...I am an addiction researcher with 30+ years in the field and recently published an article titled "An Economon Model of Drug Addiction" that may be of interest to you: PMID: 38277005. I have enjoyed reading your series of NY Times articles; thanks for your work.

@CodySiciliano @TheCalipariLab @alewis1982 @TheErinCalipari and (4) doing some basic pharmacology with the ligands: dose-effect curves, time course, tolerance, etc.

Behavior shouldn’t be an afterthought in neuroscience. Had a good time writing this opinion piece with @alewis1982 & @TheErinCalipari. We highlight common design pitfalls & argue for standardization to help push the field forward. Read more: eneuro.org/content/8/2/EN…

@CodySiciliano @TheCalipariLab @alewis1982 @TheErinCalipari (2) correlating individual differences in expression and behavioral effects, (3) determining infection-induced changes in cell physiology as reported in Gold et al 2016 PMID: 27798132.../3

@CodySiciliano @TheCalipariLab @alewis1982 @TheErinCalipari (1) dissociation between infection and expression patterns for highly similar control vs. experimental viral vectors (e.g. mCherry vs. mCherry-DREADD vectors) /2

@CodySiciliano @TheCalipariLab @alewis1982 @TheErinCalipari But would be good to have some guidelines too focused on use of these tools for circuit manipulation...some examples of things that could be addressed: /1

@CodySiciliano @TheCalipariLab @alewis1982 @TheErinCalipari Nice article with useful cautionary tales that apply not only to chemo/optogenetic studies, but studies of behavior with any independent variable...including drugs

@PainlabQ @INRCmeeting We should be using preclinical assays that can distinguish MOR and KOR agonists. Assays of pain-depressed behavior offer one approach. There are others. See Pharm Rev 71:225-266, 2019 PMID: 30898855 for discussion./End

@PainlabQ @INRCmeeting More important point is that conventional preclinical assays that rely on pain-stimulated behaviors cannot distinguish between MOR agonists that are effective analgesics and centrally acting KOR agonists that are not. That's a problem./2

@PainlabQ @INRCmeeting Caveat here is that I am discussing centrally acting KOR agonists including U50,488, enadoline, salvinorin A, nalfurafine. Surprised if this is controversial. Does anyone really think centrally acting KOR agonists are useful to treat pain?/1